[Tumor resistance to multiple antineoplastic agents mediated by glycoprotein P: from the laboratory to the clinical field].
González-Manzano
R
R
Departamento de Oncología, Clínica Universitaria de Navarra, Pamplona.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D004351:Drug Resistance; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins
Resistencia tumoral a múltiples agentes antineoplásicos mediada por glucoproteína P: del laboratorio a la clínica.